LabEx ReFi - European Laboratory on Financial Regulation

CENTOGENE to Participate in Upcoming Conferences in March

Retrieved on:

星期三, 三月 8, 2023

Journal of Inherited Metabolic Disease, Myotonia congenita, Genetic testing, Congress, LabEx ReFi - European Laboratory on Financial Regulation, Conference, Inborn errors of metabolism, Diagnosis, Innovation, Pharmaceutical industry, Online shopping, Pharma

CENTOGENE representatives will be attending events in Brazil, the U.S., Saudi Arabia, Thailand, and the U.K. and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities.

Key Points:

CENTOGENE representatives will be attending events in Brazil, the U.S., Saudi Arabia, Thailand, and the U.K. and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities.
Please see additional details below:
To learn more about the 3rd Brazilian Congress of Neurogenetics 2023 and set up an in-person meeting with the CENTOGENE team, please visit the event webpage ( https://link.centogene.com/3KK0jgi ).
To learn more about the 6th Asian Congress on Inherited Metabolic Diseases 2023 and set up an in-person meeting with the CENTOGENE team, please visit the event webpage ( https://link.centogene.com/3ZpRrRe ).
To learn more about the European Laboratory Research & Innovation Group’s (ELRIG) Research & Innovation 2023 conference and set up an in-person meeting with the CENTOGENE team, please visit the event webpage ( https://link.centogene.com/3YKdpOh ).

ComplianceTech Announces the Refresh of the Home Mortgage Disclosure Act Data in LendingPatterns to Include 2021 Data

Retrieved on:

星期三, 四月 6, 2022

ComplianceTech today announces the refresh of the Home Mortgage Disclosure Act (HMDA) data in LendingPatterns to include the 2021 data as published by the CFPB on March 24, 2022.

Key Points:

ComplianceTech today announces the refresh of the Home Mortgage Disclosure Act (HMDA) data in LendingPatterns to include the 2021 data as published by the CFPB on March 24, 2022.
Using the 2021 HMDA data from every lender in the U.S., LendingPatterns can pinpoint fair lending issues related to underwriting, pricing, steering, and redlining.
Geographical analysis options include, the entire U.S., metro areas, state, county, city, congressional districts, and lenders CRA assessment areas.
There are 4,186 lenders reporting data for 23.2 million applications in 2021, a drop of 6.6% in HMDA reporters.

Aro Biotherapeutics to Highlight Therapeutic Potential of Centyrin Oligonucleotide Conjugates at Upcoming Industry Conferences

Retrieved on:

星期三, 三月 30, 2022

Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, LabEx ReFi - European Laboratory on Financial Regulation, Therapy, RNA transfection, Biotechnology, Conference, Protalix BioTherapeutics, Tissue, Industry, Glycogen storage disease type II, Gaming Innovation Group, Protein, Disease, Fine chemical

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced upcoming data presentations highlighting the therapeutic potential of its proprietary Centyrin oligonucleotide conjugate therapies.

Key Points:

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced upcoming data presentations highlighting the therapeutic potential of its proprietary Centyrin oligonucleotide conjugate therapies.
In the upcoming presentations, Aro scientists will present new in vivo proof-of-concept data demonstrating advantages of its Centyrin oligonucleotide platform for achieving potent and specific inhibition of disease-causing mRNAs and proteins in selected disease relevant tissues.
Furthermore, the presentations will highlight the modularity of the platform for tissue targeting of both siRNA and antisense oligonucleotides conjugated to receptor specific Centyrins.
Our team looks forward to sharing the scientific data that validates the broad potential of Centyrin-oligonucleotide conjugates to address genetic diseases with high unmet medical needs, said Susan Dillon, Ph.D., co-founder and Chief Executive Officer of Aro Biotherapeutics.